Ontology highlight
ABSTRACT:
SUBMITTER: Santos FP
PROVIDER: S-EPMC4406395 | biostudies-literature | 2012 Oct
REPOSITORIES: biostudies-literature
Santos Fabio P S FP Verstovsek Srdan S
Hematology/oncology clinics of North America 20120821 5
The development of JAK2 inhibitors followed the discovery of activating mutation of JAK2 (JAK2V617F) in patients with classic Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPN). It is now known that mutations activating the JAK-STAT pathway are ubiquitous in Ph-negative MPN, and that the deregulated JAK-STAT pathway plays a central role in the pathogenesis of these disorders. JAK2 inhibitors thus are effective in patients both with and without the JAK2V617F mutation. This artic ...[more]